Sintilimab may trigger autoimmune GFAP astrocytopathy in esophageal squamous cell carcinoma patients
New cancer treatment may cause rare brain inflammation in patients
This case report and literature review describes a patient with advanced esophageal squamous cell carcinoma who developed autoimmune GFAP as…
A new type of immunotherapy for esophageal cancer can trigger a rare brain condition, requiring doctors to watch for early signs of neurolog…
Aumolertinib Combined with Chemotherapy Improves Progression Free Survival in EGFR Mutated NSCLC
Combination therapy extends progression free survival in lung cancer
Phase 3 trial results show aumolertinib plus chemotherapy significantly extends progression-free survival compared to monotherapy for advanc…
A new trial shows that combining a specific drug with chemotherapy helps patients with advanced lung cancer live longer without their diseas…
Second-line immunotherapy combination with etoposide and capecitabine improves extracranial disease control in pulmonary choriocarcinoma
New treatment combinations show promise for rare lung cancer
This systematic review and case report analyze 45 cases of primary pulmonary choriocarcinoma. A second-line combination of camrelizumab, eto…
A new combination of immunotherapy and chemotherapy may help control the spread of a rare type of lung cancer called pulmonary choriocarcino…
Multidisciplinary management of mixed adenoneuroendocrine carcinoma of the gallbladder involves surgery and adjuvant chemotherapy
Rare gallbladder cancer type shows specific genetic markers and traits
This case report and literature review describes the clinical management of a patient with mixed adenoneuroendocrine carcinoma of the gallbl…
A rare form of gallbladder cancer, known as GB-MANEC, was identified in a patient who underwent surgery and chemotherapy with no recurrence …
NLRP3 inflammasome modulates immune evasion and chemotherapy sensitivity in gynecological cancers
New research identifies a key driver in gynecological cancer cells
This mini-review examines the role of the NLRP3 inflammasome in ovarian, endometrial, and cervical cancers. It highlights how NLRP3 impacts …
A protein called NLRP3 helps certain cancers hide from the immune system, but it also plays a complex role in how tumors react to treatment.
Cisplatin-based chemotherapy associated with superior survival over carboplatin in advanced bladder cancer
Cisplatin shows better survival for patients with bladder cancer
This meta-analysis of 2543 patients found that cisplatin-based regimens are associated with significantly better overall survival and cancer…
New data reveals that cisplatin-based chemotherapy leads to longer survival than carboplatin for many people with advanced bladder cancer.
Reduced-dose craniospinal radiation and smaller volume boost for medulloblastoma patients
Trial Shows Reduced Radiation May Help Children With Medulloblastoma
This randomized phase 3 trial evaluated reduced-dose craniospinal radiation (18.00 Gy) and a smaller volume boost in children aged 3 to 7 wi…
A large clinical trial looked at whether reducing radiation doses for children with medulloblastoma can maintain safety and effectiveness.
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
Immunotherapy combo extends survival in small cell lung cancer
This phase 3 RCT evaluated tislelizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated extensive-stage small cel…
Adding tislelizumab to chemo helped people with extensive-stage small cell lung cancer live 2 months longer, a phase 3 trial shows.
Chemo-immunotherapy yields 12-month disease-free status in rare triple-negative neuroendocrine breast cancer
A single patient remains disease-free after a new chemo-immunotherapy approach for rare breast cancer
This case report describes a 71-year-old woman with triple-negative neuroendocrine breast cancer treated with paclitaxel, cisplatin, and pem…
A 71-year-old woman with rare breast cancer stayed disease-free for a year using a combination of chemotherapy and immunotherapy that doctor…
20-fraction hypofractionated radiotherapy passes noninferiority for tumor control and late toxicity in locally advanced head and neck cancer
Shorter radiation schedule works as well for head and neck cancer
This randomized, open-label, Phase 3 noninferiority trial enrolled 792 patients with locally advanced head and neck squamous cell carcinoma …
A shorter radiation plan for head and neck cancer showed the same effectiveness as a longer schedule while reducing late side effects.
Irinotecan plus cisplatin shows no RFS benefit over etoposide plus cisplatin in resected lung HGNEC
Five-year follow-up shows irinotecan plus cisplatin matches etoposide plus cisplatin for lung cancer survival
This randomized, open-label, phase III study compared irinotecan plus cisplatin to etoposide plus cisplatin in 221 patients with resected hi…
A five-year look at lung cancer patients found that irinotecan plus cisplatin worked just as well as etoposide plus cisplatin for keeping th…
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients
In younger patients with mantle cell lymphoma, adding ASCT to an ibrutinib regimen did not improve outcomes but increased toxicity. Ibrutini…
Adding stem cell transplant to ibrutinib did not improve survival for younger lymphoma patients but increased side effects.
All cisplatin Articles
- Sintilimab may trigger autoimmune GFAP astrocytopathy in esophageal squamous cell carcinoma patients
- Aumolertinib Combined with Chemotherapy Improves Progression Free Survival in EGFR Mutated NSCLC
- Second-line immunotherapy combination with etoposide and capecitabine improves extracranial disease control in pulmonary choriocarcinoma
- Multidisciplinary management of mixed adenoneuroendocrine carcinoma of the gallbladder involves surgery and adjuvant chemotherapy
- NLRP3 inflammasome modulates immune evasion and chemotherapy sensitivity in gynecological cancers
- Cisplatin-based chemotherapy associated with superior survival over carboplatin in advanced bladder cancer
- Reduced-dose craniospinal radiation and smaller volume boost for medulloblastoma patients
- Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
- Chemo-immunotherapy yields 12-month disease-free status in rare triple-negative neuroendocrine breast cancer
- 20-fraction hypofractionated radiotherapy passes noninferiority for tumor control and late toxicity in locally advanced head and neck cancer
- Irinotecan plus cisplatin shows no RFS benefit over etoposide plus cisplatin in resected lung HGNEC
- Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
- FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
- Meta-analysis shows neoadjuvant chemoradiation improves resection and survival outcomes for esophageal squamous cell carcinoma patients compared to chemotherapy alone
- Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
- Pre-treatment body composition and acute kidney disease risk in head and neck cancer patients treated with cisplatin
- Neoadjuvant Chemoimmunotherapy Alters Tumor Microenvironment in Esophageal Cancer
- Case report details long-term survival in appendiceal signet-ring cell carcinoma with uterine involvement
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in Chinese adults with advanced biliary tract carcinoma
- Early study of CDP1 plus chemotherapy showed promising activity and manageable safety in advanced penile cancer
- Durvalumab plus chemotherapy improves event-free and overall survival in muscle-invasive bladder cancer compared to chemotherapy alone
- Phase 3 trial compares IMPT versus IMRT plus cisplatin in locally advanced oropharyngeal squamous cell carcinoma
- Penpulimab plus chemotherapy significantly improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma
- Exploratory RCT finds in situ vaccine plus PD-1 with immunoradiotherapy shows response in advanced hepatic malignancies
- Phase II trial finds adding gemcitabine to cisplatin-radiotherapy does not improve 2-year disease-free survival in muscle-invasive bladder cancer
- Phase I study finds amrubicin-cisplatin with radiotherapy feasible in limited-stage SCLC
- Phase 3 trial of pembrolizumab plus chemo for advanced biliary tract carcinoma posts results
- Platinum-based intraperitoneal chemotherapy improves disease-free survival after curative CRC resection
- Induction Nivolumab Before CRT Misses Feasibility Threshold in High-Risk HPV+ OPC
- Triapine Added to Cisplatin and Radiation for Cervical/Vaginal Cancer: Phase III Results